Floatz logo

Finerenone

Heart Failure

Hospital de Messejana Dr. Carlos Alberto Studart GomesSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

26 Active assets in the Heart Failure cohort.

Asset / SponsorPhaseRating
Empagliflozin
Jacob Moller
Phase 4BB
CARVEDILOL
Abramson Cancer Center at Penn Medicine
Phase 3BB
Semaglutide
University Medical Centre Ljubljana
Phase 2/3BB
Rivaroxaban
Janssen Research & Development, LLC
Phase 3B
Dapagliflozin
University Medical Centre Ljubljana
Phase 3B

View all 40 →

Same molecule, other indications

Finerenone is also rated in:

diabetic kidney diseaseDormant
B
Indicative ·
62 / 100
View asset →
HyperkalemiaDormant
B
Indicative ·
62 / 100
View asset →
chronic kidney diseaseDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →